🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Refractory Solid Tumors

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies NCT04678648Phase 13 sites📍 Los Angeles📍 Denver📍 Nashville RasCal Therapeutics, Inc. · Tests: RSC-1255 Dose Escalation, RSC-1255 Dose Expansion CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors NCT05733000Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor NCT06615193Phase 18 sites📍 Zhengzhou📍 Suzhou📍 Suzhou Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Tests: HDM2005 A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors NCT06730659Phase 11 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: CHT101 GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453Phase 1, Phase 213 sites📍 New York📍 New York📍 Huntersville GI Innovation, Inc. · Tests: GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases NCT07697937Phase 21 site📍 Tianjin Tianjin First Central Hospital · Tests: YH-02 A Study of PHST001 in Advanced Solid Tumors NCT06840886Phase 120 sites📍 Beverly Hills📍 Los Angeles📍 Palo Alto Pheast Therapeutics · Tests: PHST001, Paclitaxel, Topotecan, Doxorubicin, FOLFIRI Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors NCT06320405Phase 1, Phase 21 site📍 Portland OHSU Knight Cancer Institute · Tests: Axatilimab, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours NCT06430502NA1 site📍 Wuxi Wuxi People's Hospital · Tests: Tumor Treatment Vaccine; PD-1/L1 inhibitors TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma NCT07189195Phase 11 site📍 Sacramento University of California, Davis · Tests: TR-002 ML-016 in Advanced Cancer With Lung and/or Liver Involvement NCT07723482Phase 1, Phase 23 sites📍 Miranda📍 Wollongong📍 Buderim BrYet US, Inc. · Tests: ML-016 CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors NCT05410717Phase 11 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981Phase 17 sites📍 Detroit📍 St Louis📍 Canton Sairopa B.V. · Tests: ADU-1805, Pembrolizumab HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors NCT07800936Phase 11 site📍 Changchun Parr Biotechnology (Hebei) Co., Ltd. · Tests: HP007 Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors NCT06940349Phase 1, Phase 21 site📍 Petah Tikva Rabin Medical Center · Tests: Palbociclib, Sunitinib A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors NCT06063681Phase 13 sites📍 Randwick📍 Clayton📍 Frankston Stingray Therapeutics · Tests: SR-8541A, Immune checkpoint inhibitor (ICI) IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors NCT06014502Phase 113 sites📍 Gilbert📍 Orange📍 Santa Monica ImmunoGenesis · Tests: IMGS-001 Evaluate the Safety and Clinical Activity of HH2853 NCT04390737Phase 1, Phase 225 sites📍 Phoenix📍 Jacksonville📍 Rochester Haihe Biopharma Co., Ltd. · Tests: HH2853 Tablets Pemigatinib + Afatinib in Advanced Refractory Solid Tumors NCT06302621Phase 11 site📍 Boston Massachusetts General Hospital · Tests: Afatinib, Pemigatinib A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma NCT05341557Phase 14 sites📍 Chaoyang📍 Cangzhou📍 Tianjin Betta Pharmaceuticals Co., Ltd. · Tests: BPI-371153 Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors. NCT06173219Phase 1, Phase 21 site📍 Beijing China-Japan Friendship Hospital · Tests: Radiotherapy combined with immunotherapy A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies NCT05669430Phase 1, Phase 213 sites📍 Los Angeles📍 Denver📍 New Haven GV20 Therapeutics · Tests: GV20-0251, GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], GV20-0251 and Pembrolizumab [KEYTRUDA®] A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. NCT07016997Phase 12 sites📍 Nagaizumicho📍 Chuo-Ku Chiome Bioscience Inc. · Tests: CBA-1535, CBA-1535+Pembrolizumab Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors NCT06132503Phase 11 site📍 West Valley City Lantern Pharma Inc. · Tests: LP-284 Combination of CAR-DC Vaccine and ICIs in Malignant Tumors NCT05631886Phase 11 site📍 Beijing Chinese PLA General Hospital · Tests: TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide, anti-PD-1 antibody, Anti-CTLA4 Monoclonal Antibody Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer NCT05111561Phase 14 sites📍 Boston📍 Boston📍 Galveston National Cancer Institute (NCI) · Tests: BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors NCT06956690Phase 1, Phase 27 sites📍 La Jolla📍 Indianapolis📍 Farmington Hills Hummingbird Bioscience · Tests: ENV-501
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy